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Abstract
Background: The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous
influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in
HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent
inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. (clinicaltrials.gov Identifier:NCT01066169)
Methods and Findings: In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (FocetriaH, Novartis)
was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21).
Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The
seroprotection rate (defined as HI titers $1:40) for HIV-infected patients was 88% after the first and 91% after the second
vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the
immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%).
Seroprotective titers at baseline were much more common in those who had received 2009–2010 seasonal TIV three weeks
prior to the first dose of pH1N1 vaccine. Using stored serum samples of 51 HIV-infected participants we measured the
pH1N1 specific response to 2009–2010 seasonal TIV. The seroprotection rate to pH1N1 increased from 22% to 49% after
vaccination with 2009–2010 seasonal TIV. Seasonal TIV induced higher levels of antibodies to pH1N1 in older than in
younger subjects.
Conclusion: In HIV-infected patients on combination antiretroviral therapy, with a median CD4+ T-lymphocyte count above
500 cells/mm3, one dose of MF59-adjuvanted pH1N1 vaccine induced a high seroprotection rate comparable to that in
healthy controls. A second dose had a modest additional effect. Furthermore, seasonal TIV induced cross-reactive antibodies
to pH1N1 and this effect was more pronounced in older subjects.
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Introduction
Most guidelines recommend annual influenza vaccination of all
HIV-infected patients [1]. The rationale for this recommendation is
that in the era of widespread use of combination antiretroviral therapy
(cART) influenza is still associated with increased rates of morbidity in
HIV-infected patients [2,3] and that vaccination prevents disease [4,5].
The immunogenicity of adjuvanted 2009 pandemic influenza
A(H1N1) (pH1N1) vaccines in HIV-infected patients and the effect
of recent and past trivalent inactivated influenza vaccines (TIV) is a
matter of current interest. We measured the humoral immune
response to a monovalent MF59-adjuvanted surface-antigen vaccine
containing 7,5 mg hemagglutinin of strain A/California/7/2009
(H1N1) (X-181) (FocetriaH, Novartis) in HIV-infected patients and in
healthy controls. In addition we tested whether recent vaccination with
seasonal TIV induced cross-reactive antibodies to pH1N1.
Methods
Ethics statement
This study was approved by the ethics committee of Leiden
University Medical Center (protocol number 09.187). Subjects
provided written informed consent for participation in the study
and for the use of stored serum samples for the purpose of this
study.
Study design and source population
This was a single-center prospective cohort study at Leiden
University Medical Center in The Netherlands. The pH1N1
vaccine was administered twice to 58 adult HIV-infected patients
(patients) and 44 healthy hospital employees (controls) in
November and December 2009 (day 0 and day 21). Exclusion
criteria were: use of systemic immunosuppressive medication,
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ongoing febrile illness, pregnancy or laboratory confirmed pH1N1
influenza before the first vaccination. At inclusion, participants were
asked whether they had experienced symptoms of influenza in the
two preceding months. In addition, all participants filled out a
standardized diary on symptoms of influenza during the 56 day
follow-up period. Influenza-like illness was defined as sudden onset
of fever of .38uC and cough or sore throat in the absence of other
diagnoses [6]. Serum was collected at baseline, at day 21 (just before
the second dose) and at day 56 (35 days after the second dose). In a
subset of 51 participants (29 patients and 22 controls) serum was also
collected at day 7. We retrieved stored serum samples of a subset of
51 HIV-infected patients who had been vaccinated with unadju-
vanted 2009–2010 seasonal trivalent inactivated influenza vaccine
(TIV) a month before receiving the first pH1N1 vaccination. In
addition, we retrieved stored samples of 14 of these 51 HIV-infected
patients who had also participated in an influenza vaccination trial
in 2005 [7]. There were no such samples available of the healthy
controls. The stored serum samples were used to measure whether
2009–2010 and 2005–2006 seasonal TIV induced cross-reactive
antibodies to pH1N1 influenza.
Laboratory analysis and main outcome measures
Antibodies to the vaccine strain A/California/7/2009 (H1N1)
and to the seasonal influenza vaccine strains A/NewCaledonia/
20/1999 and A/Brisbane/59/2007 were measured using the
hemagglutination-inhibition (HI) assay, according to standard
methods [8]. Titers below the detection limit (i.e. ,1:10) were
assigned a value of 1:5. Geometric mean titers (GMTs) and
seroprotection rates (defined as HI titers $1:40) were the main
outcome measures. Seroconversion was defined by a post-
vaccination HI titer of at least 1:40 combined with at least a
four-fold increase in titer in accordance to European and
international guidance [9,10].
Statistical methods
The between group difference in GMT taken over the three
time points (day 0, 21, 56) was analyzed using a mixed linear
model. This model takes into account that each subject had
repeated measurements of the HI titer over time. We analyzed
which variables predicted the level of post-vaccination GMT in
the group of HIV-infected patients using a linear regression model
with step-wise introduction of the continuous variables ‘log of the
HI titer at baseline’, ‘age in years’, ‘CD4+ T-lymphocyte count
(cells/mm3)’, ‘nadir CD4+ T-lymphocyte count (cells/mm3)’ and
the categorical variables ‘HIV-1 RNA’ (,20 copy/ml, 20–400
copy/ml, .400 copy/ml) and ‘gender’. Proportions were
compared with Pearson x2 or Fisher’s exact tests as appropriate.
We explored which variables were associated with a baseline HI
titer of $1:40 using a logistic regression model by step-wise
introduction of the continuous variable ‘age’ and the categorical
variables ‘HIV-status’ (i.e. infected or healthy control), ‘gender’,
‘an influenza-like illness prior to inclusion’, ‘vaccination with
2009–2010 seasonal influenza vaccine’, ‘vaccination with 2008–
2009 seasonal influenza vaccine’ and ‘vaccination with 2007–2008
seasonal influenza vaccine’.
In an exploratory analysis we looked at the effect of age on the
level of cross-reactive antibodies to pH1N1 following 2009–2010
seasonal TIV using a linear regression model with step-wise
introduction of the continuous variables ‘age in years’, ‘CD4+ T-
lymphocyte count (cells/mm3)’, ‘nadir CD4+ T-lymphocyte count
(cells/mm3)’ and the categorical variable ‘HIV-1 RNA’. This
analysis was restricted to HIV-infected patients who had received
seasonal TIV before pH1N1 vaccine and who had no measurable
HI titer to pH1N1 prior to receiving 2009–2010 seasonal TIV.
Results
Follow-up was complete for 98% (57/58) of HIV-infected
patients and all healthy controls. The mean age of the patients was
52 (SD 11) years and of the controls 49 (SD 10) years. Of the
patients, 91% (52/57) was on cART of whom 87% (45/52) had
undetectable plasma HIV-1 RNA (,20 copies/mL) at baseline.
The median CD4+ T-lymphocyte count was 507 (IQR 349-697)
cells/mm3 and only three patients had a count below 200 cells/
mm3. In the month preceding inclusion, 89% (51/57) of HIV-
infected patients and 64% (28/44) of controls had been vaccinated
with non-adjuvanted 2009-2010 seasonal TIV (Table 1).
Three patients (5%) and 3 controls (7%) reported an influenza-
like illness in the two months preceding inclusion, of whom 2
patients and 1 control had a baseline HI titer $1:40. The baseline
GMT was higher in patients (23, 95% CI 15–35) than in controls
(12, 95% CI 8–16) (Figure 1a). At baseline, 44% (25/57) of
patients and 23% (10/44) of controls had a HI titer $1:40. Titers
above 80 were uncommon at baseline (Figure 1b).
Immunogenicity results are summarized in Figure 1 and
Table 2. In a mixed linear model, the age-adjusted average
GMT taken over the three time points after vaccination was a
factor 1.6 higher in controls than in HIV-infected patients (95%
CI 1.0-2.5, p= 0.06) (Figure 1a). In a linear regression model
restricted to the HIV-infected patients, only higher baseline titers
(p= 0.02) were associated with higher HI titers at day 21. This
association was not seen at day 56.
The seroprotection rate, defined as a titer $1:40, was 88% (50/
57) for HIV-infected patients three weeks after the first pH1N1
vaccination and 91% (52/57) after the second vaccination. For
controls this was 93% (41/44) and 89% (39/44) respectively
(Figure 1b). In a separate analysis, restricted to participants with a
baseline titer below the detection limit, the seroprotection rate was
72% (18/25) for HIV-infected patients after the first and 88% (22/
25) after the second vaccination. For the controls this was 89%
(24/27) and 85% (23/27).
After the first vaccination only 53% (30/57) of HIV-infected
patients achieved seroconversion compared with 73% (32/44) of
controls. After the second vaccination this was 63% (36/57) and
70% (31/44) (Table 2). The GMT was lower in those who did not
seroconvert than in those who did. The GMT in HIV-infected
patients who did not seroconvert was 72 (95% CI 42–124) and was
161 (95% CI 122–212) in those who did seroconvert. For controls
this was 61 (95% CI 25–147) and 347 (95% CI 233–516). As is to
be expected, seroconversion rates were lower in those with high HI
titers at baseline. In a separate analysis of 25 HIV-infected patients
who had HI titers below the detection limit at baseline, 72% (18/
25) achieved seroconversion after the first pH1N1 vaccination and
88% (22/25) after the second vaccination. For the 27 controls this
was 89% (24/27) and 85% (23/27).
After the first vaccination, between day 0 and day 21, an
influenza-like illness was reported by 5 HIV-infected patients (9%)
and 6 controls (14%). Of these participants, 4/5 patients (80%)
and 6/6 controls (100%) had a HI titer $1:40 at day 21. In
addition, one patient and 1 control reported an influenza-like
illness between day 21 and day 56 of follow-up. Both had HI titer
$1:40 at day 56.
There were no serious adverse events following vaccination and
HIV-1 RNA remained below the detection threshold in a random
selection of 20 patients with undetectable viral loads at baseline.
All except 1 of the 35 subjects with a baseline pH1N1 titer
$1:40 had received 2009–2010 seasonal TIV. Prior vaccination
with 2009–2010 seasonal TIV (OR 14, 95% CI 2–113, p = 0.01)
and higher age (OR 1.04, 95% CI 1.0–1.1 for an increase in age
pH1N1 Vaccine and HIV
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by 1 year, p = 0.05) were associated with a baseline pH1N1 HI
titer $1:40.
Using stored serum samples of 51 of the HIV-infected patients
we measured the pH1N1 specific response to 2009–2010 seasonal
TIV administered a median of 17 days (IQR 14–23 days) before
the first pH1N1 vaccination. We found that the seroprotection
rate to pH1N1 increased from 22% to 49% following vaccination
with 2009–2010 seasonal TIV and that 31% seroconverted
(Table 2). This effect was age dependent. In a regression analysis
restricted to 40 HIV-infected patients who all had undetectable HI
titers to pH1N1 prior to vaccination with 2009–2010 seasonal
TIV, we found that 2009–2010 seasonal TIV induced higher HI
titers in older than in younger subjects (HI titer increased by a
factor 1.05 95% CI 1.01–1.08 for an increase in age by 1 year,
p = 0.01). This effect was independent of the CD4+ T-lymphocyte
count, nadir CD4+ T-lymphocyte count and HIV-1 RNA. Of
note, we found no evidence indicating that the immune response
to pH1N1 vaccine was augmented by prior vaccination with
seasonal TIV.
In a subset of 14 HIV-infected patients we measured (cross-
reactive) pH1N1 HI titers following three different influenza
vaccinations (i.e. 2005–2006 seasonal TIV, 2009–2010 seasonal
TIV and pH1N1 vaccine). In 2005 the seroprotection rate to
pH1N1 for this cohort of 14 HIV-infected patients increased from
14% to 43% after vaccination with 2005–2006 seasonal TIV
(Table 3). In 2009 the seroprotection rate to pH1N1 had dropped
back to 7% but increased to 50% after vaccination with 2009–
2010 seasonal TIV. The subjects who developed cross-reactive
antibodies to pH1N1 after 2005–2006 seasonal TIV were not
necessarily the same subjects who did so after 2009–2010 seasonal
TIV (p = 0.5, Fisher’s exact test for the association between
seroconversion to pH1N1 following 2005–2006 seasonal TIV and
2009–2010 seasonal TIV).
Discussion
In HIV-infected patients on cART, with a median CD4+ T-
lymphocyte count above 500 cells/mm3, one dose of MF59-
adjuvanted 2009 pandemic influenza A(H1N1) vaccine induced a
Table 1. Participant Demographics.
HIV-infected
n=57
Healthy
Control
n=44
Male - n (%) 48 (84) 27 (61)
Age, years - mean (SD) 52 (11) 49 (10)
Age categories - n (%)
18–44 years 14 (25) 12 (27)
45–59 years 26 (46) 28 (64)
.60 years 17 (30) 4 (9)
combination antiretroviral
therapy (cART) - n (%)
52 (91) -
baseline value CD4+ T-lymphocytes,
cells/mm3 - median (IQR)
507 (349–697) -
CD4 category, at the time
of vaccination n (%)
-
,350 cells/mm3 14 (25) -
.350 cells/mm3 43 (75) -
nadir CD4+ T-lymphocytes,
cells/mm3 - median (IQR)
143 (32–281) -
baseline HIV-1 RNA - n (%) -
,20 copy/ml 45 (79) -
20-400 copy/ml 7 (12) -
.400 copy/ml 5 (9) -
past seasonal trivalent inactivated
influenza vaccination - n (%)
2009–2010 51 (89) 28 (64)
2008–2009 50 (88) 27 (61)
2007–2008 45 (79) 29 (66)
doi:10.1371/journal.pone.0016496.t001
Figure 1. Immunogenicity of two doses of pH1N1 vaccine. Monovalent MF59-adjuvanted pandemic influenza vaccine (A/California/7/2009)
administered to a group of 57 HIV-infected patients (HIV) and 44 healthy controls (HC). The vaccine was administered at day 0 (baseline) and at day
21. Age adjusted geometric mean titers with 95% confidence intervals at baseline, day 7, day 21 and day 56 (Panel A). Reverse cumulative distribution
curves on hemagglutination inhibition assay at baseline and at day 21 (Panel B).
doi:10.1371/journal.pone.0016496.g001
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high rate of seroprotection comparable to that in healthy controls.
The second dose showed no effect on GMT 5 weeks after it had
been administered, but it did have a modest additional effect on
the seroprotection rate in HIV-infected patients. Post-vaccination
GMT was lower in HIV-infected patients than in healthy controls.
Furthermore we found that seasonal TIV induced seroprotection
to pH1N1 in just under half of the participants and that this effect
was more pronounced in older subjects.
There are three published studies and there is one set of
preliminary data on the humoral response to a single dose of 2009
pandemic influenza A(H1N1) vaccine in comparable groups of
HIV-infected patients (Table 4) [11–14]. This study is the first to
report the effect of this particular vaccine in HIV-infected patients
and the first to report the effect of a second dose in HIV-infected
patients. It is also the only study on pH1N1 vaccine in HIV-
infected patients that included a comparator control group. In two
of the other studies with ASO3-adjuvanted vaccine, the seropro-
tection rate exceeds 90%. A third study reports a lower
seroprotection rate. In a head to head comparison, squalene
based adjuvanted influenza vaccine clearly outperforms unadju-
vanted influenza vaccine in HIV-infected patients [11], as has also
been found for healthy adults [15]. Due to relatively high baseline
HI titers, the seroconversion rate in our study was lower than in
other studies. A fourfold increase in titer is more difficult to
achieve if the baseline titer is already high. This reasoning is in line
with the fact that we found higher seroconversion rates for the
participants who had undetectable pH1N1 HI titers at baseline.
Our interpretation of the data is that most participants in our
study were clinically protected following vaccination with MF59-
adjuvanted pH1N1 vaccine.
In this study just under half of the participants had a HI titer
$1:40 at baseline, i.e. at or above the threshold that defines
seroprotection. Although the peak incidence of the influenza
pandemic in the Netherlands coincided with the start of the
vaccination campaign [16], less than 10% had a recent influenza-
like illness before receiving the first pH1N1 vaccine. Therefore, it
seems unlikely that infection with influenza accounted for the high
seroprotection rate at baseline. There was a strong association
between recent vaccination with 2009–2010 seasonal TIV and
seroprotection at baseline. This association was confirmed by
analyses of stored serum samples, which showed that 2009–2010
seasonal TIV induced cross-reactive antibodies to pH1N1 and that
2005–2006 seasonal TIV had a comparable effect. In other studies
baseline seroprotection rates vary from 0 to approximately 30%
[15,17–27]. Some studies do [17,20,26] and others do not [23,24]
report an association between baseline HI titers to pH1N1 and
prior vaccination with seasonal TIV. The fact that we found a
stronger association between vaccination with seasonal TIV and
induction of cross-reactive antibodies to pH1N1 than most other
studies can be due to a number of reasons. Firstly, as opposed to
most other studies, the majority of subjects in our study had
received 2009–2010 seasonal TIV before inclusion. Secondly, the
time between having received seasonal influenza vaccine and
pH1N1 vaccine was much shorter in our study than in other
studies. Lastly, we studied HIV-infected patients and it could be
that this group produces larger quantities of cross-reactive
Table 2. Humoral immune response to two doses of pH1N1 vaccine.
HIV-infected n=57 Healthy Control n=44
prior 2009-2010 seasonal TIV prior 2009-2010 seasonal TIV
Yes
n=51
No
n=6
All
n=57
Yes
n=28
No
n=16
All
n=44
pre-baseline, before 2009-2010 seasonal TIV (day –95)*
HI titer $1:40 - n (%) 11 (22) - - - - -
GMT – value (95% CI) 9
(7–12)
- - - - -
baseline, after 2009–2010 seasonal TIV but before 1st pH1N1 vaccine (day 0)
HI titer $1:40 - n (%) 25 (49) 0 25 (44) 9 (32) 1 (6) 10 (23)
GMT – value (95% CI) 28
(18–42)
5 (-) 23
(15–35)
15
(9–25)
7
(5–9)
12
(8–16)
after 1st pH1N1 vaccine (day 21)
HI titer $1:40 - n (%) 47 (92) 3 (50) 50 (88) 25 (89) 16 (100) 41 (93)
seroconversion – n (%)# 27 (53) 3 (50) 30 (53) 16 (57) 16 (100) 32 (73)
GMT – value (95% CI) 119
(87–163)
57
(16–193)
110
(81–150)
117
(69–198)
632
(422–947)
216
(139–334)
after 2nd pH1N1 vaccine (day 56)
HI titer $1:40 - n (%) 47 (92) 5 (83) 52 (91) 23 (82) 16 (100) 39 (89)
seroconversion – n (%)# 31 (61) 5 (83) 36 (63) 15 (54) 16 (100) 31 (70)
GMT – value (95% CI) 138
(101–187)
107
(58–200)
134
(101–178)
117
(73–186)
572
(384–853)
208
(140–310)
Seroprotection- and seroconversion rates and geometric mean titers (GMT) to 2009 pandemic influenza A(H1N1) (pH1N1) virus for 57 HIV infected individuals and 44
healthy controls following vaccination with two doses of monovalent MF59-adjuvanted pandemic influenza vaccine (A/California/7/2009). Results are stratified by
whether or not participants had been vaccinated with 2009–2010 seasonal trivalent inactivated influenza vaccine (TIV) before receiving the first pH1N1 vaccine.
*For 51 HIV-infected participants who had already been vaccinated with 2009–2010 seasonal TIV at baseline (day 0), we also determined HI titers to 2009 pandemic
influenza A(H1N1) virus in stored serum samples that had been collected before they received 2009–2010 seasonal TIV.
#Baseline titers (day 0) were used as denominaters to determine seroconversion rates.
doi:10.1371/journal.pone.0016496.t002
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antibodies upon vaccination because of a less well regulated B-cell
immune response [28,29].
Using virus neutralization assays, others have shown that cross-
reactive antibodies that are induced by seasonal TIV are functional
against pH1N1 [30]. This entails that these antibodies do confer
protection against pH1N1. There is epidemiological evidence that
supports this claim although there is also evidence to the contrary
[31–34]. The surface hemagglutinin and neuraminidase proteins in
recent seasonal trivalent inactivated influenza vaccines are antigen-
ically very distant from those of pH1N1. Therefore seasonal TIV is
generally not expected to confer a significant degree of cross-
protection to pH1N1 [35]. Only older age by way of exposure to
pre-1957 influenza strains has consistently been found to confer a
relevant degree of cross-reactive antibodies to pH1N1 [17,36–39].
In this respect it is interesting that we found that seasonal TIV was
more likely to induce cross-reactive antibodies to pH1N1 in older
than in younger subjects, which contradicts the conclusion of
Hancock et al. who found that seasonal TIV induces little to no
cross-reactive antibody response to pH1N1 in any age group. We
think that our findings show that seasonal influenza vaccines do not
induce a relevant degree of cross protection to pH1N1 in (younger)
immunologically naı¨ve subjects but that seasonal influenza vaccines
can boost relatively unrelated influenza specific memory B-cells. In
older individuals who have been exposed to influenza strains or
vaccines that are antigenically more related to pH1N1, such
boosting induces measurable levels of antibodies to pH1N1, which
may augment clinical protection against pH1N1.
This study has strengths and limitations. It was a prospective
well controlled cohort study in a fairly homogenous group in
which follow-up was complete for 99% of participants. This study
is unique in that it shows the immune response to vaccination with
pH1N1 and the effect of seasonal influenza vaccines in the same
HIV-infected patients. Although symptoms of an influenza-like
illness were systematically assessed, respiratory samples were not
collected to confirm pH1N1 infection and therefore intercurrent
infections can not be excluded. However, only 11 participants had
an influenza-like illness between day 0 and day 21. Regarding the
generalizability of our results: 91% of our HIV-infected patients
were successfully being treated with combination antiretroviral
therapy (cART) and very few HIV-infected participants had a
CD4+ T-lymphocyte count below 200 cells/mm3.
In conclusion, a single dose of MF59-adjuvanted 2009
pandemic influenza A(H1N1) vaccine in HIV-infected patients
on cART with a median CD4+ T-lymphocyte count above 500
cells/mm3 induced a high rate of seroprotection comparable to
that in healthy controls. A second dose had a modest additional
effect in HIV-infected patients but not in healthy controls. Post-
vaccination GMT, a sensitive marker of the immune competence
of a group, was lower in HIV-infected patients than in healthy
controls, reflecting the underlying immunodeficiency. Further-
more we found that recent seasonal TIV induced a high rate of
age-dependent cross-reactive seroprotection to pH1N1. We think
that in general, seasonal TIV boosts pre-existent influenza specific
memory B-cells. In older people who in the past have been
Table 3. (Cross-reactive) antibody titers following two different seasonal influenza vaccines in a cohort of 14 HIV-infected patients.
HIV-infected (n=14)*
influenza strain used in HI assay A/NewCaledonia/20/1999 (seasonal strain) A/California/7/2009 (pandemic strain)
Before 2005–2006 seasonal TIV
HI titer $1:40 - n (%) 7 (50) 2 (14)
GMT – value (95% CI) 39 (16–92) 10 (5–17)
after 2005–2006 seasonal TIV
HI titer $1:40 - n (%) 11 (79) 6 (43)
seroconversion - n (%) 4 (29) 3 (21)
GMT – value (95% CI) 118 (52–272) 21 (10–45)
influenza strain used in HI assay A/Brisbane/59/2007 (seasonal strain) A/California/7/2009 (pandemic strain)
Before 2009–2010 seasonal TIV
HI titer $1:40 - n (%) 12 (86) 1 (7)
GMT – value (95% CI) 55 (34–90) 6 (4–9)
after 2009–2010 seasonal TIV but before 1st pH1N1 vaccine
HI titer $1:40 - n (%) 14 (100) 7 (50)
seroconversion - n (%) 2 (14) 6 (43)
GMT – value (95% CI) 103 (57–187) 23 (12–43)
after 1st pH1N1 vaccine
HI titer $1:40 - n (%) - 13 (93)
seroconversion - n (%) - 8 (57)
GMT – value (95% CI) - 114 (62–209)
Seroprotection- and seroconversion rates and geometric mean titers (GMT) to 2005–2006 seasonal influenza A(H1N1) virus, to 2009–2010 seasonal influenza A(H1N1)
virus and to 2009 pandemic influenza A(H1N1) (pH1N1) virus for 14 HIV infected individuals following vaccination with seasonal trivalent inactivated influenza vaccine
(TIV) in 2005 (A/New Caledonia/20/1999 (H1N1) like strain), with seasonal TIV in October 2009 (A/Brisbane/59/2007 (H1N1) like strain) and with a first dose of
monovalent MF59-adjuvanted pH1N1 vaccine (A/California/7/2009) in November 2009.
*Population characteristics in 2009: 86% male, median age 48 years (IQR 47–66), 86% on cART, median CD4+ T-lymphocytes 532 cells/mm3 (IQR 349–725), baseline HIV-1
RNA 71% ,20 copy/ml, 14% 20–400 copy/ml, 14% .400 copy/ml. Population characteristics in 2005: 64% on cART, median CD4+ T-lymphocytes 473 cells/mm3 (IQR
285–752), baseline HIV-1 RNA 57% ,50 copy/ml, 14% 50–400 copy/ml, 29% .400 copy/ml.
doi:10.1371/journal.pone.0016496.t003
pH1N1 Vaccine and HIV
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exposed to influenza strains that are antigenically more alike to
pH1N1, this effect induces measurable levels of cross-reactive
antibodies to pH1N1. If such an effect is true and if it adds to
clinical protection against pH1N1, it is an additional benefit of
annual influenza vaccination.
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